Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference

NESS ZIONA, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will present a Company overview and business update at the following upcoming virtual investor conferences:

Jefferies Healthcare Conference (June 1 – 4, 2021)
Speaker:	Dr. Alon Seri-Levy, Chief Executive Officer
Date:	Tuesday, June 1, 2021
Time:	8:30 – 8:55 am EDT
Raymond James Human Health Innovation Conference
(June 21 – 23, 2021)
Speaker:	Dr. Alon Seri-Levy, Chief Executive Officer
Date:	Tuesday, June 22, 2021
Time:	10:00 – 10:30 am EDT

A recording of the webcast of each presentation will be available in the Investors/Events & Presentations section of the Company’s website at www.sol-gel.com.

About Sol-Gel Technologies

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of TWYNEO®, under investigation for the treatment of acne vulgaris with an NDA filed with the FDA and a PDUFA goal date set for August 1, 2021; and EPSOLAY®, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date set for April 26, 2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.

For further information, please contact:

Sol-Gel Technologies

Gilad MamlokChief Financial Officer+972-8-9313433

Investor relationsIrina KofflerLifeSci Advisors+1-917-734-7387[email protected]

Source: Sol-Gel Technologies Ltd.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
• Marie Brizard Wine & Spirits: Q1 2024 revenues
• Federal Home Loan Bank of New York Announces First Quarter 2024 Operating Highlights